The Nexus Principals The four principals of the Nexus Group are exceptionally qualified as private equity investors. They have worked together as a team for several years. Averaging 20 years in the business and experienced in global markets, they are well-versed in all aspects of selecting, vetting and investing in emerging growth companies engaged in the life science and medical device fields. They also have exceptional track records as hands-on investors in adding value to their portfolio companies by their strategic inputs and their introductions to sources of capital and technology.     Edwin Snape, PhD.   Dr. Snape, co-founder and head of the healthcare practice at Nexus, has been involved in private equity investing for the past 25 years. He has founded and/or had a role in the management of nine private equity funds aggregating approximately $400 million. These include two UK funds, three US funds, two Pacific Rim funds, one ASEAN fund and one corporate fund. He has been directly responsible for founding or investing in over 30 companies in the medical device/life sciences sector. He was a founder of The Liposome Company. He has co-invested with most of the leading venture capital and private equity firms in the US and the UK and has established an extensive network of contacts in the entrepreneurial, investment banking, legal and accounting communities. Prior to his investment career, Dr. Snape authored numerous technical papers and holds several patents in the advanced materials field. He holds B.S. and PhD degrees from the University of Leeds, England.     John F. Rousseau, Jr.   As a co-founder of Nexus, Mr. Rousseau has worked closely with Dr. Snape for ten years, investing in healthcare companies spanning medical devices, biotechnology, diagnostics, medical instruments and healthcare services, including Harvard Bioscience (drug discovery instruments), Minrad International (image guidance and specialty pharmaceuticals), and Santarus (proprietary products for gastrointestinal diseases). Prior to his business career, Mr. Rousseau practiced law for fifteen years and was a Senior Partner at the Boston-based law firm of Hale and Dorr. He holds a B.A. from Amherst College, and a J.D. from Columbia Law School.     Thomas E. Hancock   Mr. Hancock has over fourteen years experience in the biopharmaceutical industry and equity capital markets. At Nexus he has been responsible for several investments, including A&G Pharmaceuticals, Stheno Corporation and Panacos Pharmaceuticals. Prior to joining Nexus, he was a Senior Equity Analyst and Managing Director at US Bancorp Piper Jaffray, covering both the biopharmaceutical and drug discovery tools markets. Previously, he worked in the biopharmaceutical industry at both Genentech, Inc. and COR Therapeutics, Inc. in a number of roles including business development and project management. Mr. Hancock has a BS in Molecular Biology and an MBA from UC Berkeley.     Gregory F. Zaic   Mr. Zaic has over 20 years of venture capital investment experience, focused on companies in the medical device/life sciences area. He has had a role in the management of six venture capital funds, and has served on numerous boards of directors of both public and private companies. Prior to joining Nexus, Mr. Zaic was a general partner of Prince Ventures, an independent, medically focused, venture capital partnership. At Prince, he was responsible for successful investments in Xylos Corporation (biosynthetic materials) and PerSeptive Biosystems (bioseparations products). Prior to Prince Ventures, Mr. Zaic was Vice President and Special Limited Partner of the Vista Group where he worked closely with Ed Snape, leader of Vista's health care practice. Before Vista, Mr. Zaic ran the Special Products division for Baxter Laboratories. Mr. Zaic received a B.S. degree in aerospace and mechanical engineering from Princeton University, an M.S. in mechanical engineering and an M.S. in management (Sloan School of Management) both from the Massachusetts Institute of Technology.     Affiliate In addition to the four Principals, Nexus has an affiliate based in Munich. Kai Deusch, MD heads Medicis Nexus (Munich). He is an entrepreneur and has been active in healthcare for more than 25 years. He contributes long standing experience in clinical practice, clinical and basic research as well as in management, private equity and corporate finance. Dr. Deusch started his entrepreneurial activities at McKinsey as co-founder of McKinsey's New Venture Practice for advising young companies in life science and healthcare. In 1999, Dr. Deusch founded Medicis, a venture capital holding company focused on early stage investments in life science. Dr. Deusch successfully sold Medicis's entire portfolio in 2001. Subsequently Dr. Deusch was recruited to lead the German healthcare team of Apax Partners, an internationally recognized private equity firm. Prior to founding Medicis Nexus in 2006, Dr. Deusch executed direct private equity investments and provided both M&A and strategic advisory services in the field of healthcare in cooperation with Doertenbach & Co (Frankfurt). Dr Deusch was instrumental in the recent sale of Megapharm, a Euro 390 million revenues specialty oncology wholesaler, to UK's Alliance Boots/KKR. Dr. Deusch sits on the Board of Mast Biosurgery, PathoLase (observer), Aethon (observer), and Deltex Medical Holdings (observer).     Advisors Howard Maibach, M.D., Professor in the Department of Dermatology at the University of California, San Francisco. Dr. Maibach is a recognized expert in the field of Dermatology, and specifically, dermatopharmacology and dermatotoxicology. Dr. Maibach has published over 1700 articles on various dermatology-related subjects, and is a frequent lecturer on various subjects related to dermatology. Dr. Maibach has been on the editorial boards of over 30 scientific journals and is a member of 19 professional societies including the American Academy of Dermatology, San Francisco Dermatological Society, and the International Commission on Occupational Health. His bibliography contains 1,950 publications.     Tadaharu Wakabayashi of Tokyo. Wakabayashi-san is past President of SmithKline Beecham Seiyaku and is currently a consultant to Japanese, American and European pharmaceutical companies who desire to develop their business in Japan. He is also an advisor for the Pharmaceutical Division of Nissan Chemical, Co., Ltd. Wakabayashi-san also mediated the establishment of Nisshin Kyorin Seiyaku KK, a joint venture between Nisshin Flour Milling and Kyorin Pharmaceutical in April 1996.